TABLE 2

Effect of 3-week treatment with GR-ASO on liver glycogen, triglyceride, and plasma enzymes in db/db mice

TreatmentLiver weight (g)Plasma AST (mg/ml)Plasma ALP (mg/ml)Plasma ALT (mg/ml)Liver glycogen (μmol/g wet tissue)
Liver triglyceride (mg/g wet tissue)
FedFastedFedFasted
Control ASO2.0 ± 0.1117 ± 9112 ± 7122 ± 13373 ± 19222 ± 1438.6 ± 3.557.9 ± 4.8
GR ASO3.1 ± 0.1*146 ± 11107 ± 3196 ± 26309 ± 16*124 ± 21*69.5 ± 6.8*112.0 ± 6.6*
  • Data are means ± SE, with n = 8 for each group. Diabetic mice received a 3-week treatment with either control ASO or GR-ASO. Blood samples were collected at the end of the study. Plasma levels of aspartate aminotransferase (AST), alkaline phosphatases (ALPs), and alanine aminotransferase (ALT) were analyzed as described in research design and methods. Liver tissue samples were collected by freeze-clamp method to measure glycogen and triglyceride contents.

  • *

    * P < 0.01,

  • P < 0.05 compared with the same parameter in the control ASO–treated group.